# Developmental Funds

> **NIH NIH P30** · UNIVERSITY OF CHICAGO · 2020 · $4,734

## Abstract

ABSTRACT
Over the past five years, Developmental Funds have been used to support Pilot Projects, recruitment of new
investigators, and development of new Shared Resources and services to further UCCCC strategic goals,
including a) Precision Medicine and the UCCCC Personalized Cancer Care Consortium (PCCC); b) Cancer
Prevention and Population Medicine; and c) Cancer Survivorship, Outcomes, and Economics as well as
interdisciplinary and interprogrammatic collaborations. From 2013-2016, a CCSG investment of $939,622 has
yielded a remarkable return of $12,456,464 in peer-reviewed support, as well as publications and
programmatic development. Support for four new investigators has contributed to enhancements of the
Molecular Mechanisms of Cancer, Clinical and Experimental Therapeutics, and Cancer Prevention and Control
Programs. Recruitments include: Megan McNerney, MD, PhD, a physician scientist who focuses on the
genomics of therapy-related and de novo acute myeloid leukemias (AML), and molecular diagnostics; David
VanderWeele, MD, PhD, who studies tumor heterogeneity, with a focus on genitourinary malignancies; Akash
Patnaik, MD, PhD, who is a translational physician scientist working at the interface between laboratory-based
investigations and early-phase clinical trials in prostate cancer; and Jane Churpek, MD, who is a clinician/
researcher who focuses on hereditary cancer susceptibility syndromes with an emphasis on hematological
malignancies. Four new developing Shared Resources or new services were supported with CCSG
Developmental Funds: the Human Imaging Research Office (HIRO), Imaging Chemistry Subcore within the
Integrated Small Animal Imaging Research Resource, the development of CRISPR/Cas9 technology in the
Transgenic Mouse and ES Cell Facility, and the Bioinformatics Core Facility, the latter is now proposed as a
full Core. The developing Cores continue to grow and contribute to interdisciplinary research.
Over the next grant period, we are requesting $300,000/year for: 1) recruitment of new investigators
($100,000); 2) Program development/Program Pilot Projects ($100,000); and 3) development of new Shared
Resources and the development of new services and integration of new technologies ($100,000). These funds
will be used to further the three components of our Strategic Plan: 1) developing new biomarkers, novel
treatments, and new interventions to prevent cancer; 2) efficiently integrating effective treatments and
interventions into medical practice; and 3) assessing the impact of these new approaches on health outcomes,
and addressing cancers relevant to our catchment area. Underpinning each of these initiatives is computation-
based models for cancer research and care.

## Key facts

- **NIH application ID:** 10178312
- **Project number:** 3P30CA014599-45S2
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** MICHELLE M LE BEAU
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,734
- **Award type:** 3
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10178312

## Citation

> US National Institutes of Health, RePORTER application 10178312, Developmental Funds (3P30CA014599-45S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10178312. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*